Unusual Drug Fever Caused by Imipenem/Cilastatin and a Review of Literature
Introduction: Drug fever is a febrile reaction caused by initiation of one drug or varieties of drugs and often disappears after cessation of the drug(s). Clinically, drug fever is frequently induced by antibiotics, anticonvulsants, and antineoplastics. There are few previous reports about drug fever caused by imipenem/cilastatin.
Case Presentation: Here, we described a 66-year-old man undergoing the Ivor Lewis esophagectomy for esophageal carcinoma, who developed drug fever. The patient had a high temperature with shivering after administration of imipenem/cilastatin for 7 days. Furthermore, his temperature came down after discontinuing imipenem/cilastatin and receiving steroids. Body temperature increased rapidly
4 hours after intravenous readministration of imipenem/cilastatin and rapidly decreased to normal after discontinuing imipenem/cilastatin and administering steroids.
Conclusion: Thorough history, blood tests, physical examination, and computed tomography (CT) did not reveal any evidence of fever. Drug fever caused by imipenem/cilastatin was considered. We also present a review of relevant literature and provide a point of reference for the clinical diagnosis and therapy of patients with drug fever.
Cunha BA. 2007. Fever of unknown origin: clinical overview of classic and current concepts. Infect Dis Clin North Am 21(4):867-915.
Cunha BA. 2013. Clinical approach to fever in the neurosurgical intensive care unit: Focus on drug fever. Surg Neurol Int 4(suppl 5):S318-22.
Fang Y, Xiao H, Tang S, Liang L, Sha W, Fang Y. 2016. Clinical features and treatment of drug fever caused by anti-tuberculosis drugs. Clin Respir J 10(4):449-54.
Foong KS, Lee A, Pekez M, Bin W. 2016. Imipenem/cilastatin-induced acute eosinophilic pneumonia. BMJ Case Rep 2016:bcr2016214804.
Hornik CP, Herring AH, Benjamin DK Jr, et al. 2013. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 32(7):748-53.
Johnson DH, Cunha BA. 1996. Drug fever. Infect Dis Clin North Am 10(1):85-91.
Kalambokis G, Vassou A, Bourantas K, Tsianos EV. 2005. Imipenem-cilastatin induced pure white cell aplasia. Scand J Infect Dis 37(8):619-20.
Li Z, Shen J, Li Q, Chan MT, Wu WK. 2015. Drug fever induced by piperacillin/tazobactam in a scoliosis patient: a case report. Medicine (Baltimore) 94(46):e1875.
Linares T, Fernández A, Soto MT, Escudero E, Gacías L. 2011. Drug fever caused by piperacillin-tazobactam. J Investig Allergol Clin Immunol 21(3):250-1.
Naschitz JE. 2011. Drug fever induced by ertapenem. QJM 104(8):730-1.
Ninan J, George GM. 2016. Imipenem-cilastatin-induced psychosis: a case report. J Med Case Rep 10:107.
Ochi H, Wada K, Okada H, et al. 2011. The persistence of drug-induced fever by teicoplanin--a case report. Int J Clin Pharmacol Ther 49(5):339-43.
Park HB, Choi JS, Park SH, Kee WJ, Koh YI. 2011. Drug fever due to piperacillin/tazobactam loaded into bone cement. J Korean Med Sci 26(2):301-3.
Patel RA, Gallagher JC. 2010. Drug fever. Pharmacotherapy 30(1):57-69.
Pleasants RA, Walker TR, Samuelson WM. 1994. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 106(4):1124-8.
Shao QQ, Qin L, Ruan GR, Chen RX, Luan ZJ, Ma XJ. 2015. Tigecycline-induced drug fever and leukemoid reaction: a case report. Medicine (Baltimore) 94(45):e1869.
Vodovar D, LeBeller C, Mégarbane B, Lillo-Le-Louet A, Hanslik T. 2012. Drug Fever: a descriptive cohort study from the French national pharmacovigilance database. Drug Saf 35(9):759-67.
Young EJ, Fainstein V, Musher DM. 1982. Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population. Rev Infect Dis 4(1):69-77.
Yuan HL, Lu NW, Xie H, Zheng YY, Wang QH. 2016. Doxycycline-induced drug fever: a case report. Infect Dis (Lond) 48(11-12):844-6.
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).